EP4340815A1 — Novel oral liquid compositions of enzalutamide and method of manufacturing thereof
Assigned to BDR Pharmaceuticals International Pvt Ltd · Expires 2024-03-27 · 2y expired
What this patent protects
The present invention relates to oral liquid formulations of Enzalutamide or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. Further, the invention relates to providing an economical and technically advanced dosage form over existin…
USPTO Abstract
The present invention relates to oral liquid formulations of Enzalutamide or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. Further, the invention relates to providing an economical and technically advanced dosage form over existing dosage forms. In addition, the present invention also provides an improved process for preparation of Enzalutamide oral liquid formulation. The present invention further provides such compositions for the treatment of for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
Drugs covered by this patent
- Marinol (DRONABINOL) · Wellhouse Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.